The telecoms group has bought a 51% stake in its portfolio company Invenium, a mobility data analytics company spun out of TU Graz.

The insulation breakage measuring device producer is joining Ampacimon having launched out of Polytechnic University of Madrid over ten years ago.

PureTech Health, Johnson & Johnson and Novartis are in line for exits after the cancer drug developer filed for its initial public offering.

The immunotherapy developer plans to go public in the United States having raised $565m from investors including Eli Lilly and WuXi AppTec.

Cambrian Biopharma is the largest investor in cancer immunotherapy developer Sensei Biotherapeutics, which has filed to raise up to $100m.

Biohaven has purchased the 58% stake cancer immunotherapy developer Kleo Pharmaceuticals it did not already own.

Existing shareholder Biohaven has agreed to purchase the remaining stake in Kleo Pharmaceuticals, a Yale spinout it first backed in 2016.

Klingel subsidiary K-Invest is set to exit the online content analysis tool provider in a purchase of undisclosed size by peer Unicepta.

The drama content producer, which counts iQiyi among its investors, has gone public in Hong Kong and seen its share price rise 84% on its first day of trading.

The stem cell therapy developer has filed to go public seven months after closing $700m in funding from investors including Alphabet unit GV.